Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: justmickey who wrote (69614)	11/3/2000 6:52:17 AM
From: cavan	Respond to of 150070

DNAP,Thanks Mickey!

To: justmickey who wrote (69614)	11/3/2000 6:15:24 PM
From: Jim Bishop	Read Replies (1) \| Respond to of 150070

DNAP 8K filed SARASOTA, Fla.--(BUSINESS WIRE)--Nov. 3, 2000--DNAPrint genomics, Inc. (Pink Sheets:DNAP) today announced that it has filed a complete form 8-k with the Securities and Exchange Commission (SEC) which provides detailed disclosure of the merger with SDE Holdings 1, Inc., including financial disclosures. "We are pleased to have completed this filing which will facilitate the dissemination of complete information about the Company and its progress," stated Chief Scientific Officer Dr. Tony Frudakis. Dr. Frudakis added, "Upon completion of appropriate regulatory reviews, the Company intends to file its forms to trade on the NASD Bulletin Board. ABOUT DNAPRINT GENOMICS, INC. DNAPrint genomics, Inc. provides practitioners of genomic research and personalized medicine with a comprehensive system for complex trait dissection and patient classification. DNAPrint genomics Inc. was founded by a group of scientists with research and commercial experience in high-level mathematical modeling, programming and molecular genetics. On October 17th, the Company announced that it merged with a SEC 12g full reporting company, and expects to be trading on the OTC Bulletin Board within 30 days. The 12g merger did not cause the Company any dilution, and the share structure, trading symbol and name will all remain identically as they existed prior to the 12g merger. For more information about the company, please visit www.DNAPrint.com All statements in this press release that are not historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. These and other risk factors are discussed in the Company's Form 8-k filed with the Securities and Exchange Commission on November 3, 2000. DNAPrint expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. --30--bl/mi* CONTACT: DNAPrint genomics, Inc., Sarasota For Scientific inquiries: Tony Frudakis, Ph.D., 941/351-4543 or Other inquiries Richard Craig Hall, 941/341-0136 KEYWORD: FLORIDA INDUSTRY KEYWORD: BIOTECHNOLOGY MEDICAL MERGERS/ACQ Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: businesswire.com * end of story *